证券代码:300463 证券简称:迈克生物 公告编号:2026-006 迈克生物股份有限公司 关于实际控制人部分股份质押及解除质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于近日收到实际控制人之一唐勇先生的通知， 获悉唐勇先生将其持有的部分股份办理了质押式回购交易手续、并将部分已质押股份办理了解 除质押交易手续，现将具体情况公告如下： 一、本次股东股份质押的基本情况 2026 年 3 月 2 日，公司实际控制人之一唐勇先生将其持有的部分公司股份 17,920,000 股 办理了质押式回购交易手续，情况如下： | 是否为 | 股 | 是否 | 第一大 | 占其所 | 占公司 | 是否 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | 本次质押 | 为补 | 质押起 | ...

证券代码:300463 证券简称:迈克生物 公告编号:2026-005 二、对公司的影响 本次获得注册证的全自动尿有形成分分析仪U 650系公司尿液平台新仪器产品，可高效满 足临床实验室高通量、高精准、即时化的检测需求，进一步完善了医学检验全场景项目布局， 丰富了体外诊断产品矩阵，有助于提升公司在院内检验场景的综合服务能力。 铜蓝蛋白测定试剂盒（免疫比浊法）系公司生化平台新试剂产品，主要用于肝豆状核变性 （Wilson病）疾病的辅助诊断。戊型肝炎病毒IgM抗体检测试剂盒（直接化学发光法）新产品 系公司直接化学发光平台新试剂产品，主要用于戊型肝炎病毒急性感染或近期感染的辅助诊断， 第 1 页 共 2 页 证券代码:300463 证券简称:迈克生物 公告编号:2026-005 该产品配套公司全自动化学发光免疫分析仪i 6000、i 3000系列、i 1000系列与i 800系列。截至 目前，公司在直接化学发光平台下已累计取得142项试剂类产品注册证（涵盖甲状腺功能、传 染病、心肌、肿瘤标志物、贫血、炎症、自身免疫性疾病、生殖激素、骨代谢等病种检测）。 迈克生物股份有限公司 关于公司及全资子公司新产品取得产品注册证 ...

Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

Core Insights - The digital PCR (dPCR) technology is emerging as a significant advancement in nucleic acid detection, providing more precise and sensitive methods for quantitative analysis, addressing limitations of traditional PCR methods [1][10] - The Chinese digital PCR market is projected to grow from 1.584 billion yuan in 2019 to 8.815 billion yuan by 2025, with a compound annual growth rate (CAGR) of 33.1% [1][10] - The growth is driven by technological advantages and supportive national policies, with increasing recognition of its value among researchers and clinicians [1][10] Industry Overview - Digital PCR is categorized into droplet digital PCR (ddPCR) and chip digital PCR (cdPCR), allowing for absolute quantification without relying on standard curves, suitable for single-cell analysis and early cancer diagnosis [3][4] - The technology offers significant advantages over traditional PCR, including higher sensitivity, accuracy, and better tolerance to complex samples [4][5] Market Dynamics - The digital PCR industry is supported by a robust supply chain, with upstream components including essential biological materials and core parts like optical and fluid control components [6] - The midstream involves the research, production, and sales of digital PCR devices, with notable domestic companies like New Yi Biological and Zhenzhun Biological emerging as competitors [6][7] Application Areas - Digital PCR is utilized in various fields, including clinical diagnostics for pathogen detection, research for gene expression analysis, food safety testing, and agricultural applications [7][8] - In clinical settings, it plays a crucial role in early disease diagnosis and monitoring, particularly in oncology and infectious diseases [8] Competitive Landscape - The digital PCR market in China has seen the emergence of several domestic companies, with 16 manufacturers winning bids in 2024, of which 11 are local brands [12][12] - New Yi Biological and Linghang Gene lead in market share, with respective bid shares of 20% and 17.14% [12] Future Trends - Continuous technological innovation is expected to enhance detection efficiency and reduce costs, with advancements in multi-color fluorescence detection and microfluidic chip technology [16][17] - Collaboration among upstream suppliers, midstream manufacturers, and downstream application sectors will foster a synergistic development environment [17] - There is a growing focus on expanding into international markets, with domestic companies aiming to enhance their global presence and competitiveness [18][19]

证券代码:300463 证券简称:迈克生物 公告编号:2026-004 迈克生物股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 公司 2025 年度业绩预告相关的财务数据是公司财务部门初步核算的结果，未经会计师事 务所审计。公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计师 事务所在业绩预告方面不存在分歧，具体数据以审计结果为准。 三、业绩变动原因说明 2025 年度国内行业环境发生深刻变化，集中采购、检验项目收费下调及医保支付方式改 革等政策有序落地，医疗和检测服务机构采购规模出现阶段性下行，公司坚定执行战略聚焦计 划，持续对代理产品及非核心业务进行主动剥离、优化渠道合作模式与数量，此项工作在报告 期内已基本完成，对当期收入带来了不利影响，调整后公司业务结构和渠道质量更为健康，资 源更集中于高价值的自主产品与创新解决方案。公司海外市场继续秉承积极的经营策略，报告 期内收入保持高速增长，但由于 ...

Group 1 - The Nipah virus outbreak in West Bengal, India, has reported 5 confirmed cases, with a high fatality rate of 40%-75% and no approved vaccines or treatments available globally [2][10] - The outbreak has triggered a short-lived surge in the In Vitro Diagnostics (IVD) sector in the A-share market, with significant stock price increases for companies like Cap Bio and Zhijiang Bio on January 26, followed by a rapid decline [4][12] - The IVD industry's response to the outbreak reflects a short-term reaction pattern to public health events, indicating a need to shift focus from sporadic events to long-term value driven by policy support, growing health service demand, and technological upgrades [6][15] Group 2 - The high mortality rate of the Nipah virus and the absence of specific vaccines and effective therapies have become emotional anchors for market reactions [7] - The IVD sector's core companies have seen significant price adjustments, with many stocks down over 70% from their historical highs during the COVID-19 pandemic, leading to a perception of "low valuation + oversold" conditions [7][13] - The actual demand for testing related to the Nipah virus is insufficient to sustain prolonged stock price increases, as the virus has a low transmission efficiency and primarily causes localized outbreaks [13][19] Group 3 - The IVD industry is currently experiencing a transformation phase, moving away from reliance on sporadic pandemics to a focus on regular diagnostic needs driven by an aging population and increased health awareness [19][20] - The market for medical testing in China is projected to grow from 17.97 billion yuan in 2018 to 71.92 billion yuan by 2027, with a compound annual growth rate of 19.1% [19] - Policy support, such as the "14th Five-Year Plan for National Health," aims to enhance the medical testing industry, providing a framework for technological innovation and industry upgrades [19][20]

迈克生物（300463.SZ）1月28日在投资者互动平台表示，对于近期印度尼帕病毒，公司目前暂无已获证 的尼帕病毒检测产品。公司将根据产品战略规划，从临床需求紧迫性、技术实现可行性、注册程序合规 性等多个维度进行合理评估，审慎决策，同时严格履行信息披露义务。请您关注官方信息披露渠道，谨 慎投资，注意风险。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：近期印度尼帕病毒凶猛来袭，正直年底人员流动性 大，公司有针对该病毒检测试剂相关技术储备吗？ ...

格隆汇1月28日丨迈克生物(300463.SZ)在投资者互动平台表示，对于近期印度尼帕病毒，公司目前暂无 已获证的尼帕病毒检测产品。公司将根据产品战略规划，从临床需求紧迫性、技术实现可行性、注册程 序合规性等多个维度进行合理评估，审慎决策，同时严格履行信息披露义务。请您关注官方信息披露渠 道，谨慎投资，注意风险。 ...

Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]

Core Viewpoint - The A-share biopharmaceutical sector experienced a significant rally, with multiple companies reaching the daily limit up due to the outbreak of the Nipah virus in India, which has a high mortality rate and no specific vaccine or effective treatment available [1] Group 1: Market Reaction - A-share biopharmaceutical stocks surged across the board, with companies like Mike Biologics, Cap Biologics, Zhijiang Biologics, Hualan Vaccine, and Jindike hitting the 20% daily limit up [1] - The biopharmaceutical ETF index saw a notable increase of approximately 2% in the afternoon trading session [1] Group 2: Nipah Virus Outbreak - The Nipah virus outbreak in West Bengal, India, has a mortality rate that can reach up to 75% and is transmissible between humans [1] - The Thai Civil Aviation Authority announced comprehensive screening for flights from the affected region starting from the 26th [1] - In China, the newly revised "Law of the People's Republic of China on Frontier Health and Quarantine" has included the Nipah virus in its monitoring directory [1] Group 3: Company Responses - Companies like Shuoshi Biologics and Cap Biologics have stated that they provide Nipah virus nucleic acid testing kits to assist in epidemic monitoring and port control [1] - Zhijiang Biologics mentioned that it has relevant testing products primarily sold to the Middle East, with no current orders from India [1] - The sales volume of related products is reported to be at a normal level, with a minor contribution to overall revenue [1]